While Viridian Therapeutics Inc has overperformed by 4.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VRDN rose by 37.71%, with highs and lows ranging from $27.20 to $11.40, whereas the simple moving average jumped by 27.18% in the last 200 days.
On November 25, 2024, TD Cowen started tracking Viridian Therapeutics Inc (NASDAQ: VRDN) recommending Buy. A report published by Needham on September 11, 2024, Reiterated its previous ‘Buy’ rating for VRDN. Wolfe Research also rated VRDN shares as ‘Outperform’, setting a target price of $29 on the company’s shares in an initiating report dated June 11, 2024. Goldman Initiated an Buy rating on June 06, 2024, and assigned a price target of $23. Ladenburg Thalmann May 09, 2024d its ‘Buy’ rating to ‘Neutral’ for VRDN, as published in its report on May 09, 2024. B. Riley Securities’s report from May 09, 2024 suggests a price prediction of $20 for VRDN shares, giving the stock a ‘Neutral’ rating. Credit Suisse also rated the stock as ‘Outperform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Viridian Therapeutics Inc (VRDN)
Further, the quarter-over-quarter increase in sales is 19.44%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Viridian Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -51.88% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 18.55, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and VRDN is recording an average volume of 1.53M. On a monthly basis, the volatility of the stock is set at 5.70%, whereas on a weekly basis, it is put at 5.15%, with a gain of 8.25% over the past seven days. Furthermore, long-term investors anticipate a median target price of $40.62, showing growth from the present price of $21.91, which can serve as yet another indication of whether VRDN is worth investing in or should be passed over.
How Do You Analyze Viridian Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.45%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 98.95% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VRDN shares are owned by institutional investors to the tune of 98.95% at present.
